Laromestrocel fails primary endpoint in HLHS trial
The ELPIS II trial failed to meet its primary efficacy endpoint but showed improved transplant-free survival and fewer cardiovascular events. Longeveron will explore options to maximize shareholder value.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed